These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

557 related articles for article (PubMed ID: 29721106)

  • 1. Biomarkers in Urachal Cancer and Adenocarcinomas in the Bladder: A Comprehensive Review Supplemented by Own Data.
    Reis H; Krafft U; Niedworok C; Módos O; Herold T; Behrendt M; Al-Ahmadie H; Hadaschik B; Nyirady P; Szarvas T
    Dis Markers; 2018; 2018():7308168. PubMed ID: 29721106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical sequencing identifies potential actionable alterations in a high rate of urachal and primary bladder adenocarcinomas.
    Varadi M; Nagy N; Reis H; Hadaschik B; Niedworok C; Modos O; Szendroi A; Ablat J; Black PC; Keresztes D; Csizmarik A; Olah C; Gaisa NT; Kiss A; Timar J; Toth E; Csernak E; Gerstner A; Mittal V; Karkampouna S; Kruithof de Julio M; Gyorffy B; Bedics G; Rink M; Fisch M; Nyirady P; Szarvas T
    Cancer Med; 2023 Apr; 12(7):9041-9054. PubMed ID: 36670542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telomerase reverse transcriptase (TERT) promoter mutations are rare in urachal cancer.
    Thiem S; Herold T; Krafft U; Bremmer F; Tolkach Y; Szász AM; Kriegsmann J; Gaisa NT; Niedworok C; Szarvas T; Reis H
    Pathol Int; 2017 Dec; 67(12):597-601. PubMed ID: 29047227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new technological approach in diagnostic pathology: mass spectrometry imaging-based metabolomics for biomarker detection in urachal cancer.
    Neumann JM; Niehaus K; Neumann N; Knobloch HC; Bremmer F; Krafft U; Kellner U; Nyirády P; Szarvas T; Bednarz H; Reis H
    Lab Invest; 2021 Sep; 101(9):1281-1288. PubMed ID: 34021261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of APC and PTEN Alterations in Urachal Cancer.
    Nagy N; Reis H; Hadaschik B; Niedworok C; Módos O; Szendrői A; Bíró K; Hager T; Herold T; Ablat J; Black PC; Okon K; Tolkach Y; Csizmarik A; Oláh C; Keresztes D; Bremmer F; Gaisa NT; Kriegsmann J; Kovalszky I; Kiss A; Tímár J; Szász MA; Rink M; Fisch M; Nyirády P; Szarvas T
    Pathol Oncol Res; 2020 Oct; 26(4):2773-2781. PubMed ID: 32754865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathogenic and targetable genetic alterations in 70 urachal adenocarcinomas.
    Reis H; van der Vos KE; Niedworok C; Herold T; Módos O; Szendrői A; Hager T; Ingenwerth M; Vis DJ; Behrendt MA; de Jong J; van der Heijden MS; Peyronnet B; Mathieu R; Wiesweg M; Ablat J; Okon K; Tolkach Y; Keresztes D; Nagy N; Bremmer F; Gaisa NT; Chlosta P; Kriegsmann J; Kovalszky I; Timar J; Kristiansen G; Radzun HJ; Knüchel R; Schuler M; Black PC; Rübben H; Hadaschik BA; Schmid KW; van Rhijn BWG; Nyirády P; Szarvas T
    Int J Cancer; 2018 Oct; 143(7):1764-1773. PubMed ID: 29672836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urachal carcinoma: from gross specimen to morphologic, immunohistochemical, and molecular analysis.
    Riva G; Mian C; Luchini C; Girolami I; Ghimenton C; Cima L; Novelli L; Hanspeter E; Mazzoleni G; Schwienbacher C; Pycha S; D'Elia C; Trenti E; Pycha A; Martignoni G; Hes O; Eccher A; Nesi G; Brunelli M
    Virchows Arch; 2019 Jan; 474(1):13-20. PubMed ID: 30302546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical analysis in a morphologic spectrum of urachal epithelial neoplasms: diagnostic implications and pitfalls.
    Paner GP; McKenney JK; Barkan GA; Yao JL; Frankel WL; Sebo TJ; Shen SS; Jimenez RE
    Am J Surg Pathol; 2011 Jun; 35(6):787-98. PubMed ID: 21572312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preoperative accuracy of diagnostic evaluation of urachal carcinoma.
    Ke C; Hu Z; Yang C
    Cancer Med; 2023 Apr; 12(8):9106-9115. PubMed ID: 36734315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical, prognostic, and therapeutic aspects of urachal carcinoma-A comprehensive review with meta-analysis of 1,010 cases.
    Szarvas T; Módos O; Niedworok C; Reis H; Szendröi A; Szász MA; Nyirády P
    Urol Oncol; 2016 Sep; 34(9):388-98. PubMed ID: 27267737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Urachal Cancer: an update of current molecular findings].
    Reis H; Mairinger F; Ting S; Nagy N; Witzke KE; Kohl M; Sitek B; Niedworok C; Hadaschik B; Nyirády P; Szarvas T
    Pathologe; 2019 Dec; 40(Suppl 3):239-243. PubMed ID: 31705235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anterior wall adenocarcinoma of bladder with similar clinicopathological and prognostic characteristics as common bladder carcinomas should not be treated as or classified into urachal adenocarcinomas.
    Zhou YW; Long YX; Song K; Liang LB; Cheng K; Chen Y; Liu JY
    Cancer Med; 2021 Aug; 10(16):5415-5428. PubMed ID: 34278741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical distinction between primary adenocarcinoma of the bladder and secondary colorectal adenocarcinoma.
    Wang HL; Lu DW; Yerian LM; Alsikafi N; Steinberg G; Hart J; Yang XJ
    Am J Surg Pathol; 2001 Nov; 25(11):1380-7. PubMed ID: 11684954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular Genetic Features of Primary Nonurachal Enteric-type Adenocarcinoma, Urachal Adenocarcinoma, Mucinous Adenocarcinoma, and Intestinal Metaplasia/Adenoma: Review of the Literature and Next-generation Sequencing Study.
    Pires-Luis AS; Martinek P; Alaghehbandan R; Trpkov K; Comperat EM; Perez Montiel DM; Bulimbasic S; Lobo J; Henrique R; Vanecek T; Pivovarcikova K; Michalova K; Pitra T; Hora M; Marques A; Lopes JM; Rogala J; Mareckova J; Michal M; Hes O
    Adv Anat Pathol; 2020 Sep; 27(5):303-310. PubMed ID: 32520749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma: Occurence and prognostic significance.
    Módos O; Reis H; Niedworok C; Rübben H; Szendröi A; Szász MA; Tímár J; Baghy K; Kovalszky I; Golabek T; Chlosta P; Okon K; Peyronnet B; Mathieu R; Shariat SF; Hollósi P; Nyirády P; Szarvas T
    Oncotarget; 2016 Jun; 7(26):39293-39301. PubMed ID: 27283768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimation of the incidence of urachal cancer: A systematic review and meta-analysis of registry-based studies.
    Olah C; Kubik A; Mátrai P; Engh MA; Barna V; Hegyi P; Reis H; Nyirády P; Szarvas T
    Urol Oncol; 2024 Jul; 42(7):221.e1-221.e7. PubMed ID: 38627107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Value of MRI in evaluating urachal carcinoma: A single center retrospective study.
    Das JP; Woo S; Ghafoor S; Andrieu PIC; Ulaner GA; Donahue TF; Goh AC; Vargas HA
    Urol Oncol; 2022 Jul; 40(7):345.e9-345.e17. PubMed ID: 35351368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemistry in the differential diagnosis between primary and secondary intestinal adenocarcinoma of the urinary bladder.
    Raspollini MR; Nesi G; Baroni G; Girardi LR; Taddei GL
    Appl Immunohistochem Mol Morphol; 2005 Dec; 13(4):358-62. PubMed ID: 16280666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urachal carcinoma: a clinicopathologic analysis of 24 cases with outcome correlation.
    Gopalan A; Sharp DS; Fine SW; Tickoo SK; Herr HW; Reuter VE; Olgac S
    Am J Surg Pathol; 2009 May; 33(5):659-68. PubMed ID: 19252435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progress and prospects of targeted therapy and immunotherapy for urachal carcinoma.
    Zheng Y; Peng H; Hu X; Ou Y; Wang D; Wang H; Ren S
    Front Pharmacol; 2023; 14():1199395. PubMed ID: 37324454
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 28.